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Patients with chronic heart failure (CHF) may present abnormalities
in cardiovascular, musculoskeletal and respiratory systems [1–3], and
these abnormalities may have important implications for quality of life
as well as in their poor prognosis [4]. Thus, a primary objective in the
management of these patients is to improve quality of life, and the
assessment of this variable should be an important and useful outcome
measure for evaluating beneﬁts of medical and physical therapy
interventions [5]. Randomized clinical trials (RCTs) have focused on
the effects of inspiratory muscle training (IMT) on inspiratory muscle
strength and endurance, which leads to improvement on quality of life
in thesepatients [6–8].However, the studies analysing thesebeneﬁts are
small and discordant. Therefore, we performed a systematic review
comparing IMT to control groups [placebo-IMT (the same regimen as
the IMT group, except that the treatment was performed with a lower
inspiratory load orwith no inspiratory load) or another intervention] on
quality of life in patients with CHF.
We included RCTs assessing IMT compared to control groups in the
treatment of CHF patients with the New York Heart Association (NYHA)
functional class I, II or III, follow-up longer than6 weekswhichevaluated
quality of life. We searched the following databases: MEDLINE,
Physiotherapy Evidence Database, Cochrane Central Register of Con-
trolled Trials and thebibliographies of published studies. The searchwas
performed in July 2011 and comprised the following terms: “breathing
exercises”, “inspiratory muscle training”, “respiratory muscle training”,
“heart failure” combined with a high sensitivity combination of words
used in the search for RCTs [9]. There was no language restriction. Titles
and abstracts of all articles identiﬁed were independently evaluated by
two investigators. All abstracts that did not provide sufﬁcient informa-
tion regarding the eligibility criteria were selected for full-text
evaluation and disagreement were solved by consensus.
The search strategy yielded 119 abstracts, from which four studies
were included (n=150). The reasons for exclusion of the 115 studies
were: 21 studieswith duplicated citations, 84 studies excluded based on
reviewof title and/or abstract (no CHF patients, no randomized trials, no
IMT intervention) and 10 studies excluded on secondary review (5—no
randomized trials, 2—no IMT intervention, 3—no outcome).
Three studies compared IMT to placebo-IMT [6,8,10] and one study [7]
compared IMT plus aerobic exercise (AE) to AE alone. The characteristics
of each trial are summarized in Table 1. Quality of life was assessed with
the Minnesota Living With Heart Failure Questionnaire [6,7], Disease
Speciﬁc Questionnaire [10] or Turkish version of the SF-36 [8].
Dall'Ago et al. [6] included only patients with inspiratory muscle
weakness and observed an improvement in quality of life comparing
before and after treatment measurements in the IMT group (27±17 to
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Table 1
Trial characteristics.
Study Characteristics of patients Features
Johnson et al. [10] Patients: 8/8 IMT: Threshold load 30% PImax adjusted for each increment of PImax.
Age: 70±4.6/63.4±4.5 P-IMT: Threshold load 15% PImax.
NYHA (I/II/III): 0/12/6a – Both groups: trainers for 15 min twice daily for at least 8 weeks.
Dall'Ago et al. [6] Patients: 16/16 IMT: Threshold load 30% PImax; adjusted weekly in order to maintain 30% PImax.
Age: 54±3/58±2
NYHA (I/II/III): 4/6/6/4/5/7
P-IMT: Threshold no load.
– Both groups trained 30 min daily, 7 days per week, for 12 weeks.
Bosnak-Guclu et al. [8] Patients: 16/14 IMT: Threshold load 40% PImax; training loads were adjusted weekly to maintain 40%
of the PImax.Age: 69.5±7.9/65.7±10.5
P-IMT: Threshold load 15% PImax.
NYHA (I/II/III): 0/11/5/0/9/5 – Both groups: 30 min/day, 7 days per week, for 6 weeks.
Winkelmann et al. [7] Patients: 12/12 Training group: IMT (Threshold load 30% PImax; adjusted weekly to maintain 30%
PImax—30 min daily, 7 days per week, for 12 weeks) plus aerobic exercise (supervised
exercise program performed 3 times per week, for 12 weeks).
Age: 54±12/59±9
NYHA (I/II/III): not reported
Control group: Aerobic exercise (supervised exercise program performed 3 times per
week, for 12 weeks).
IMT = inspiratory muscle training; P-IMT = placebo-inspiratory muscle training; PImax = maximal inspiratory pressure; NYHA = New York Heart Association.
a Trial did not report separate functional class for IMT versus control group;/IMT versus control group.
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6±6; Pb0.001), but not in the control group (30.1±13 to 29.6±13.1;
P=0.877). However, Winkelmann et al. [7] observed similarly improved
quality of life after both training programs (IMT plus AE=45±21
before and 20±15 after; AE=45±18 before and 18±15 after),
demonstrated no additive beneﬁt of IMT. Quality of life similarly
improved in both groups after IMT in the study by Bosnak-Guclu et al.
[8] SF-36 physical functioning, role-physical, vitality, mental health,
social functioning, bodily pain, and general health domains and also,
SF-36 physical and mental health sum scores were signiﬁcantly
improved within groups after the IMT (Pb0.05). Johnson et al. [10]
did not observe any improvement in quality of life in either group
when measuring mean changes from baseline values (IMT: +0.55±
0.48 versus control: +0.06±0.38, P=NS).
Thus, three of the four studies [6–8] did not present signiﬁcant
improvements in this outcome compared to control groups, suggesting
that IMT has no additional beneﬁcial effect on this variable. The
improvement of quality of life observed by Dall'Ago et al. [6]may be due
to the initial condition of patients who had worse functional capacity
with inspiratory muscle weakness, thus presenting a greater improve-
ment of their general condition with treatment.
In conclusion, this systematic review suggests that treatment with
IMT has no additional beneﬁt in quality of life in patients with CHF
without inspiratory muscle weakness compared to control groups.
However, the methodological quality of the studies included and the
small number of patients suggest that new randomized clinical trials
on this subject are needed for deﬁnite evidence.
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Atrial ﬁbrillation (AF) derives from a complex continuum of
predisposing factors. However, the true ‘scene of calamity’ is the
atrium. Increased left atrial (LA) size is associated with increased risk
of AF onset and recurrence, other cardiovascular disease andmortality
[1, 2]. Both atrial conduction slowing and atrial dilatation will favour
AF as it results in increased total atrial conduction time, which is the
time elapsed between the initiation of atrial depolarisation and the
last depolarisation of the same activation front [3]. A prolonged total
atrial conduction timemay reﬂect the electro-anatomical substrate for
AF since it is associated with underlying cardiovascular disease and
age [4]. It can be easily and non-invasively determined by means of
transthoracic echocardiography assessing the electromechanical PA
interval with tissue Doppler imaging (PA-TDI) [5]. Idiopathic AF refers
to AF in the absence of a cardiovascular or pulmonary disease
generating the pathophysiological substrate for the arrhythmia.
Herein, we study the electrophysiologic properties of the atria in
patients with idiopathic AF using tissue Doppler imaging.
We prospectively studied 41 consecutive idiopathic AF patients and 45
healthy sinus rhythmcontrol patientswhowere referred to the outpatient
clinic for a standard transthoracic echocardiographic examination.
Informed consent of all patients was obtained and the authors of this
manuscript have certiﬁed that they comply with the Principles of Ethical
Publishing in the International Journal of Cardiology [6].
Idiopathic AF and healthy sinus rhythmwas strictly deﬁned as the
absence of any cardiovascular disease including hypertension (no
antihypertensive drug use [diuretics, angiotensin converting enzyme
inhibitors, aldosterone receptor blockers, aldosterone receptor antago-
nists, non-dihydropyridine calcium antagonists, other], all previously
recorded systolic blood pressures not exceeding 140 mm Hg, diastolic
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